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This report is part of a series reporting the proceedings from the 
International Society of Blood Transfusion (ISBT) Working Party 
on Immunohaematology Workshop on the Clinical Significance 
of Red Blood Cell Alloantibodies. The aim of the workshop 
was to review information regarding the clinical significance 
of alloantibodies to red blood cell antigens recognized by the 
ISBT. The first 12 systems will be covered in this report. 
It is understandable that many of the most clinically important 
antibodies are directed toward antigens found in the blood 
group systems discovered earlier in history. The ABO system was 
the first to be discovered and remains the most clinically 
important regarding transfusion. Immunohematology 2019; 
35:95–101.
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The International Society of Blood Transfusion (ISBT) 
currently recognizes 36 blood group systems, which contain 
a total of 322 antigens.1 Table 1 shows the current blood group 
systems and the number of antigens within each system. The 
information presented during the Workshop on the Clinical 
Significance of Red Blood Cell Alloantibodies was collated data 
from the main review resources available, including Human 
Blood Groups by Daniels,2 The Blood Group Antigen Factsbook 
by Reid et al.,3 and key references containing information 
on the clinical significance of alloantibodies to red blood 
cell (RBC) antigens and transfusion recommendations and 
guidelines.4,5 The current validity of these data was checked 
by a PubMed search, and individual references are provided 
where required. For all other original references, please refer 
to Daniels2 and Reid et al.3
ABO Blood Group System
The ABO blood group system was the first to be 
discovered and is still the most clinically important. Despite 
consisting of just four polymorphic antigens—A, B, A,B, and 
A1—the genetics and carbohydrate chemistry underpinning 
the expression of these antigens is complex.6 Because these 
antigens are abundant on RBCs and because most adults have 
“naturally occurring” antibodies to the antigens that they lack, 
ABO antibodies are clinically significant; anti-A, -B, and -A,B 
cause severe intravascular hemolytic transfusion reactions 
(HTRs). Donor RBCs lacking the antigens corresponding to 
the antibodies in the recipient’s plasma (i.e., ABO compatible) 
must be selected for transfusion.
The one exception is anti-A1, which is rarely active at 
37°C and not generally considered clinically significant. 
Nevertheless, there have been a few rare cases of HTRs 
caused by anti-A1. Group O or indirect antiglobulin test (IAT) 
crossmatch-compatible group A RBCs should be selected.
The donor ABO blood group must also be considered 
when transfusing plasma components because of the presence 
of ABO antibodies in all but group AB donors. If group-specific 
plasma components are not available, the use of components 
known to be negative for the presence of high-titer ABO 
antibodies should be considered. Non-identical ABO group 
plasma components with high-titer anti-A and/or anti-B 
should only be given to group O recipients.
Despite clinical significance in transfusion, hemolytic 
disease of the fetus and newborn (HDFN) due to ABO 
antibodies is rare. Most ABO antibodies cannot cross the 
placenta because they are IgM and IgG2. The ABO antigens 
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are also present on tissues and within secretions of the fetus, 
preventing the antibodies from binding to the fetal RBCs. 
Furthermore, fetal ABO antigens cannot support divalent IgG 
binding because the epitopes are more linear in structure, and 
there are low levels of fetal complement.
MNS Blood Group System
The MNS system is second only to Rh for complexity 
and number of antigens in the system. Of the four common 
blood group antigens, M and N are encoded by glycophorin A 
(GYPA) and reside on the glycophorin A (GPA) glycoprotein. 
Glycophorin B (GYPB) encodes and glycophorin B (GPB) 
houses S and s. Because of the homology of the proteins, some 
N antigen is also present on normal GPB. It is because of the 
homology of GYPA and GYPB that many hybrid alleles exist, 
thus explaining the high number of antigens present in the 
system.
Most anti-M and -N are not detected by IAT at 37°C and 
are therefore not usually considered a problem for transfusion. 
Rarely, anti-M or -N is active at 37°C and is then capable of 
causing transfusion reactions. If anti-M is active by IAT at 
37°C, M– RBCs must be selected. If anti-N is active by IAT 
at 37°C, IAT-compatible RBCs may be used, since N typing 
may not be common practice. (See later for anti-N in N−U− 
individuals.)
Rarely, anti-M may cause HDFN, and when this occurs, it 
is usually severe. Anti-N has not been reported to have caused 
serious HDFN, although one case of anti-N in a N−U+var 
mother caused mild HDFN.
Anti-S and -s are often detected by IAT at 37°C and 
can cause HTRs; therefore, antigen-negative blood must be 
selected. Both anti-S and -s may cause HDFN.
Anti-U detects a high-prevalence antigen within GPB 
and has caused immediate and delayed HTRs. A homozygous 
deletion of GYPB is the most common cause of the U– 
phenotype, explaining why U– individuals are also S−s−. 
Mutations within GYPB can cause the S−s−U+var phenotypes, 
and these individuals can also make anti-U. Antigen-negative 
blood must be selected for S−s−U– individuals with anti-U. 
Patients with the S−s−U+var phenotype and anti-U can receive 
IAT-compatible S−s−U+var blood if U− blood is not available. 
Anti-U may cause HDFN.
Occasionally, anti-N present in very rare N−U– patients 
can react by IAT at 37°C with all RBCs except those of the 
N–U– phenotype. When this occurs, N–U– blood should be 
selected.
Homozygous deletion of GYPA causes the exceedingly rare 
En(a−) phenotype. There are single reports of anti-Ena causing 
a severe HTR and severe HDFN. If possible, IAT-compatible 
blood should be selected; although, because of the rarity, 
En(a−) units may not be available.
Table 1. The 36 blood group systems recognized by the ISBT
ISBT number ISBT symbol System name
Number of 
antigens
001 ABO ABO 4
002 MNS MNS 49
003 P1PK P1PK 3
004 RH Rh 55
005 LU Lutheran 25
006 KEL Kell 36
007 LE Lewis 6
008 FY Duffy 5
009 JK Kidd 3
010 DI Diego 22
011 YT Yt 5
012 XG Xg 2
013 SC Scianna 7
014 DO Dombrock 10
015 CO Colton 4
016 LW Landsteiner-Wiener 3
017 CH/RG Chido/Rodgers 9
018 H H 1
019 XK Kx 1
020 GE Gerbich 11
021 CROM Cromer 20
022 KN Knops 9
023 IN Indian 6
024 OK Ok 3
025 RAPH Raph 1
026 JMH John Milton Hagen 6
027 I I 1
028 GLOB Globoside 2
029 GIL Gill 1
030 RHAG Rh-associated glycoprotein 3
031 FORS FORS 1
032 JR JR 1
033 LAN LAN 1
034 VEL Vel 1
035 CD59 CD59 1
036 AUG Augustine 4
Data compiled from the International Society of Blood Transfusion (ISBT).1
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Antibodies often referred to as anti-Mia (including anti-
Mur and -Vw) and the antigens they define are rare in most 
regions of the world but are relatively common in people from 
East Asia. These antibodies can cause immediate and delayed 
HTRs and severe HDFN. IAT-compatible blood (most donors) 
must be selected.
P1PK Blood Group System
This system currently comprises three antigens: P1, 
Pk, and NOR. Since the discovery of the first antigen, P1 
(then called P) in 1927, the nomenclature of the system and 
the antigens within it have been through various changes, 
leading to some confusion. In addition, the association of these 
antigens with the P, PX2, and LKE antigens adds another 
element of complexity. A thorough explanation of the history 
and nomenclature aspects of the P1PK system is available in 
the review by Hellberg et al.7 The p phenotype (P–P1–Pk−) 
results from homozygosity or compound heterozygosity 
for inactivating mutations in A4GALT, which encodes the 
enzyme responsible for converting lactosylceramide to Pk and 
paragloboside to P1.
Analogous to ABO, IgM and/or IgG naturally occurring 
antibodies are usually present in the plasma of individuals 
lacking P1PK system antigens. Most P1 antibodies are 
generally weak, not reactive at or above 25°C, and do not 
cause HTRs. Rare examples of anti-P1, reactive at 37°C, have 
been reported to cause severe immediate or delayed HTRs. 
RBC units compatible by IAT at 37°C should be selected for 
transfusion to patients with anti-P1. Anti-P1 has not been 
reported to cause HDFN.
Pk is a high-prevalence antigen that is only expressed 
very weakly on most RBCs, except those of the rare P1k and 
P2k phenotypes when it is expressed strongly, and the p 
phenotype, which lacks Pk. Alloanti-Pk is found as a component 
of anti-PP1Pk in all individuals with the rare p phenotype. 
Anti-PP1Pk agglutinates or hemolyzes all RBCs except those 
of the p phenotype and is known to cause severe HTRs. There 
have been no reports of HDFN caused by anti-Pk, although 
anti-PP1Pk (in particular, the anti-P component) has been 
implicated in early spontaneous abortion, and women with the 
p phenotype have a significantly higher incidence of habitual 
abortion.
Anti-NOR recognizes a rare form of inherited 
polyagglutination found in only two families. Many adult 
antisera contain naturally occurring anti-NOR.8 There are no 
data regarding the clinical significance of anti-NOR due to the 
rarity of NOR+ RBCs.
Rh Blood Group System
All Rh antibodies should be considered potentially 
clinically significant, capable of causing both HTRs and HDFN. 
When an Rh antibody reactive by IAT (most Rh antibodies) 
is present, antigen-negative blood must usually be selected. 
Exceptions include anti-CW (see later section) and when anti-
hrS, -hrB, and e-like antibodies are detected in patients with 
variant e (see later section).
Antibodies to high-prevalence Rh antigens are rare. They 
include anti-Rh29, the antibody characteristically made by 
immunized Rhnull individuals, anti-Rh17 (anti-Hr0) produced 
by D–– individuals, and related antibodies that detect epitopes 
on the RhCcEe protein.
When anti-Rh29 is present, only Rhnull RBC units, which 
are extremely rare, are suitable. Similarly, in the presence of 
anti-Rh17, D–– RBCs should be transfused (although Rhnull 
blood will also be compatible, it should be reserved for patients 
with anti-Rh29).
For other antibodies to high-prevalence antigens including 
anti-Hr, -HrB, -Rh46, and -MAR, Rhnull or D–– blood would 
be suitable, but obtaining blood lacking the specific antigen 
should be considered to avoid unnecessary use of rare D–– 
and Rhnull units.
Anti-hrS and -hrB resemble anti-e and are typically found in 
patients of African origin with variant e. These antibodies have 
not been reported to be clinically significant, but e+var antigen-
negative blood may be considered in some circumstances (e.g., 
no hemoglobin increase after transfusion). Although R2R2 cells 
should be compatible, the patient may then be stimulated to 
produce anti-E (if the patient is E−). For E+ patients with anti-
e-like, R2R2 RBCs can be used; the alleles that result in e+var 
phenotypes are often associated with a D variant, however; 
therefore, stimulation of anti-D is a risk if a D variant has 
not been excluded (especially important in women of child-
bearing potential).
Anti-CW is a relatively common antibody but has not been 
reported to cause a transfusion reaction, and IAT-compatible 
blood may be selected (approximately 97% of donors are 
CW–). Anti-CW has been implicated in HDFN, and one case of 
hydrops fetalis, attributed to anti-CW, has been reported.9
There are many low-prevalence antigens within the Rh 
system; antibodies to these antigens should all be considered to 
have the potential to cause HDFN. Anti-Ew, -Goa, -Rh32, -Bea, 
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-Evans, and -Tar have all been implicated in HDFN. Provision 
of IAT-compatible blood for transfusion is appropriate.
Lutheran Blood Group System
The Lutheran blood group system comprises 25 antigens 
carried on a single type I membrane glycoprotein with five 
extracellular immunoglobulin superfamily (IgSF) domains. 
The glycoprotein is present on RBC surfaces in two isoforms: 
85-kDa Lu glycoprotein and 75-kDa basal cell adhesion 
molecule antigen (B-CAM), with the 85-kDa isoform being 
more abundant. Both isoforms are adhesion molecules with 
a main function of laminin binding, and both are products of 
alternative splicing of a single gene LU. Lutheran antigens are 
mostly encoded by single nucleotide mutations, resulting in 
four pairs of antithetical antigens (Lua/Lub, Aua/Aub, Lu6/Lu9, 
and Lu8/Lu14) plus an additional 17 high-prevalence antigens.
Anti-Lua has caused mild delayed HTRs (DHTRs), 
and IAT-compatible blood should be selected. Anti-Lub has 
also caused mild DHTRs; antigen-negative blood should be 
selected.
The very rare anti-Lu3 is produced by immunized 
individuals with the recessive type of Lu(a–b–) known as 
the Lunull phenotype. Lu(a−b−) blood should be selected. The 
dominant type of Lu(a−b−), known as the In(Lu) phenotype, 
is suitable and most readily available.
Other antibodies to Lutheran system high-prevalence 
antigens have not been reported to be clinically significant.10 
However, as a precaution, Lu(a−b−) blood should be selected 
for patients with strong examples of the antibodies.
Lutheran antibodies have not been implicated in severe 
HDFN; this finding may be explained by the fact that Lu 
glycoprotein is present on placental tissue, thereby preventing 
placental transfer by adsorption. Additionally, Lutheran 
antigens are poorly developed on neonatal RBCs.
Kell Blood Group System
The Kell blood group system is currently composed of 36 
antigens—23 are of high prevalence. The Kell system antigens 
reside on the Kell glycoprotein, a type II RBC transmembrane 
glycoprotein with a large, extensively folded extracellular 
domain. Most of the known Kell antigens result from single 
amino acid substitutions in the Kell glycoprotein, encoded by 
KEL.
Kell system antibodies are clinically significant and 
antigen-negative blood must be selected for transfusion, except 
in the case of anti-Kpa, in which only one case of severe DHTR 
is reported; the majority (approximately 98%) of donors will be 
Kp(a–). Anti-k has caused severe immediate HTRs. Anti-Kpb 
and anti-Jsb have also caused delayed HTRs. K+k– blood has 
a frequency of about 0.2 percent and Kp(a+b–) of about 0.01 
percent, and Js(a+b–) blood is rare in Caucasians and present 
in approximately 1 percent of the black population. Jsa has an 
occurrence of 20 percent in black individuals. Anti-Jsa has 
caused HTRs and is often found in patients with multiple 
antibodies, making identification difficult. As with all other 
antibodies to Kell system antigens, Js(a–) blood should be 
provided. Identification of Js(a–) donors has only become 
possible since the advent of molecular testing because of the 
scarcity of monospecific anti-Jsa.
Anti-Ku, the antibody produced by immunized K0 
individuals, can cause severe HTR; blood with the very rare 
K0 phenotype should be selected.
Other antibodies to high-prevalence Kell antigens are 
rare. None are reported to have caused an HTR, but antigen-
negative blood is recommended if possible. In most cases, the 
only antigen-negative blood that may be available is K0, but, 
because of its rarity, it too may not be available. For antibodies 
to low-prevalence antigens within the Kell system, IAT-
compatible blood is suitable for transfusion.
All Kell antibodies should be considered to have the 
potential to cause HDFN. There have been multiple reports of 
severe HDFN caused by antibodies to Kell system antigens.2,11 
The mechanism of the HDFN caused by Kell antibodies is 
different from that of HDFN caused by anti-D, since fetal 
anemia is thought to result from suppression of erythropoiesis 
rather than immune destruction of fetal RBCs. Therefore, fetal 
anemia occurs without the expected detectable by-products of 
hemolysis, making monitoring to predict severity of disease 
difficult.
Lewis Blood Group System
Lewis antigens are carbohydrate structures carried on 
glycolipids and glycoproteins that are adsorbed onto the RBC 
surface from plasma. Because of the biosynthesis of these 
antigens, individuals with the RBC phenotype Le(a–b+) 
do not usually produce anti-Lea. Both anti-Lea and -Leb can 
be naturally occurring antibodies produced by Le(a–b–) 
individuals. During pregnancy the Le(a–b–) phenotype can 
be acquired, and anti-Lea/-Leb can be produced.
Most examples of anti-Lea, -Leb, and -Leab are not reactive at 
37°C. Thus, although these antibodies are relatively common, 
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few examples of HTRs caused by Lewis antibodies have been 
described.2,12–14 Therefore, patients with Lewis antibodies can 
be transfused with RBCs that are compatible by IAT at 37°C.
Most anti-Leb have LebH specificity and might react 
strongly with group O RBCs but be nonreactive with group 
A1 or B RBCs. Lewis antibodies have not been implicated in 
severe HDFN, which is not surprising because Lewis antigens 
are not usually present on fetal RBCs.
Duffy Blood Group System
The antithetical Fya and Fyb antigens are carried on the 
DARC (Duffy antigen receptor for chemokines) glycoprotein 
encoded by FY. FY*A and FY*B differ by a single nucleotide, 
125G>A, encoding Gly42Asp associated with Fya and Fyb, 
respectively. The Fy(a–b–) phenotype is extremely rare in 
Caucasians, but very common in people of African origin. The 
African phenotype results from homozygosity for a mutation 
within the erythroid-specific GATA-1 transcription factor 
binding site in the promoter region of FY*B, resulting in no 
expression of DARC on RBCs.
Anti-Fya and -Fyb have caused immediate and delayed 
HTRs and antigen-negative blood must be selected. Both anti-
Fya and -Fyb have the potential to cause HDFN.
Anti-Fy3 is a rare antibody detecting antigens on all 
RBCs except those of the Fy(a–b–) phenotype. Anti-Fy3 has 
caused immediate and delayed HTRs. Fy(a–b–) blood must 
be selected.
Anti-Fy5 is a rare antibody that, like anti-Fy3, does not 
react with Fy(a–b–) but additionally does not react with Rhnull 
cells and only weakly reacts with D–– RBCs. Anti-Fy5 has 
caused delayed HTRs; thus, Fy(a–b–) blood must be selected. 
Anti-Fy3 and -Fy5 have not been implicated in severe HDFN. 
No human example of anti-Fy6 has been described.
Kidd Blood Group System
Antigens of the Kidd blood group system are carried 
on the urea transporter UT-B glycoprotein. The system 
comprises three antigens—Jka, Jkb, and Jk3—that lead to 
four phenotypes: Jk(a+b+), Jk(a−b+), Jk(a+b−), and the rare 
Jk(a–b–), Jk3− phenotype.
Antibodies to Kidd system antigens continue to be a 
significant hazard in transfusion.15 They are often difficult 
to detect because of rapidly falling to undetectable levels, 
resulting in a negative antibody detection test despite the use 
of RBCs with homozygous expression (Kidd antibodies show 
dosage). Sensitive antibody detection methods (e.g., enzyme 
IAT) may be required to detect weak antibodies.
Anti-Jka and -Jkb are common causes of delayed HTRs. 
Anti-Jka has also caused immediate HTRs. When anti-Jka or 
-Jkb are present, antigen-negative RBCs must be selected.
Antibodies to Kidd system antigens do not usually cause 
HDFN, although there are rare reports of severe HDFN caused 
by anti-Jka and anti-Jkb. Anti-Jk3 is a very rare antibody that 
reacts with all RBCs except those of the Jk(a–b–) phenotype. It 
can cause immediate and delayed HTRs. Jk(a–b–) RBCs must 
be selected for transfusion. Anti-Jk3 has not been implicated 
in HDFN.
Diego Blood Group System
The 22 antigens of the Diego blood group system reside 
on the RBC membrane protein AE1 (band 3). All antigens 
arise from a single nucleotide polymorphism in the AE1 gene. 
The system comprises three sets of antithetical antigens—
Dia/Dib, Wra/Wrb, and Wu/DISK of low and high prevalence, 
respectively—and the remaining 16 antigens are all low 
prevalence, and no antithetical high-prevalence antigens have 
been described.
Anti-Dia detects an antigen that is very rare in Caucasians, 
but is polymorphic in people of Eastern Asia and Native 
Americans. A case implicating anti-Dia in causing an HTR 
has been described, although causality was not proven, and 
the case was complicated because of the presence of additional 
alloantibodies. Anti-Dia should be considered to have hemolytic 
potential. IAT-compatible blood (most donors) should be 
selected. Anti-Dia has been implicated in severe HDFN.
Anti-Dib is a rare antibody that detects an antigen of 
very high prevalence. Anti-Dib has been implicated in HTRs 
and HDFN. Antigen-negative RBCs should be selected for 
transfusion.
Anti-Wra is a relatively common antibody to a very-low-
prevalence antigen. It has caused HTRs. IAT-compatible 
RBCs (most donors) must be selected. Anti-Wra has caused 
severe HDFN.
Anti-Wrb is a rare alloantibody to a very-high-prevalence 
antigen. There is no report of anti-Wrb causing an HTR or 
HDFN, but information is limited. If possible, antigen-negative 
blood should be selected.
Only one example of anti-DISK is known, found in the 
only known DISK− individual, and there is no information 
regarding the clinical significance of the antibody.16 Other 
antibodies of the Diego system all detect antigens of very low 
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prevalence. None has caused an HTR; IAT-compatible RBCs 
(most donors) should be selected. The only other antibody 
of the Diego system known to have caused severe HDFN is 
anti-ELO.
Yt Blood Group System
The Yt blood group system antigens are located on the 
GPI-linked RBC membrane glycoprotein, acetylcholinesterase 
(AChE). AChE exists in different isoforms in many tissues 
in the human body. Alternative splicing of ACHE encodes 
erythroid GPI-linked AChE. Although the major isoform is 
a highly conserved enzyme known to play an essential role 
in cholinergic neurotransmission at synaptic junctions, the 
role of RBC membrane–bound AChE is not yet understood. 
For the first 53 years, the Yt blood group system comprised 
two antithetical antigens: Yta, a high-prevalence antigen, and 
Ytb, a polymorphic antigen. More recently, three new high-
prevalence antigens were discovered and added to the system: 
YTEG,17 YTLI, and YTOT.18
Yt antibodies are often found in sera containing mixtures 
of antibodies. Therefore, the exclusion of clinically significant 
antibodies to common blood group antigens must be carried 
out vigilantly.
Most examples of anti-Yta are clinically benign, but rare 
cases have been reported where anti-Yta has been implicated in 
causing an HTR. Antigen-negative blood should be considered 
for strong examples of the antibody.
Anti-Ytb is very rare, and there is no report of anti-Ytb 
causing an HTR or HDFN. IAT-compatible blood should be 
selected.
Since the first example of anti-YTEG was reported in 2017, 
three additional examples have been identified.19 One example 
each of anti-YTLI and anti-YTOT have been identified. All 
of these antibodies were found in the presence of additional 
antibodies. There is no information regarding clinical 
significance with regard to transfusion. Despite multiple cases 
of Yt antibodies present during pregnancy, there are no reports 
of HDFN.
Xg Blood Group System
The Xg blood group system comprises two antigens: Xga 
(XG1) and CD99 (XG2). Both antigens are encoded by closely 
linked homologous genes CD99 (X and Y chromosome) and 
XG (X chromosome). All Xg(a+) individuals are CD99 high 
expressers; all Xg(a–) females are CD99 low expressers and 
Xg(a–) males can be CD99 high or low expressers.
Anti-Xga detects an antigen with a prevalence of 66 percent 
in males and 89 percent in females. There is no report of an 
HTR due to anti-Xga. Xga typed donor blood is generally not 
available, but IAT-compatible RBCs should be selected. Anti-
Xga has not been implicated in HDFN.
Anti-CD99 is a rare antibody: only six CD99− individuals 
with anti-CD99 have been reported.2,20 Therefore, information 
regarding clinical significance is limited to these few cases. 
No information is available regarding clinical significance for 
transfusion. Serologically least-incompatible blood should be 
used with extra caution. Anti-CD99 has not caused HDFN.2
Concluding Remarks
We have discussed the information available to us 
regarding the clinical significance of the alloantibodies to the 
antigens in the first 12 blood group systems. For many of the 
antibodies, we have substantial data available on which to base 
our understanding of the likely, or possible, clinical outcomes, 
and we can use this solid evidence base to make confident 
clinical decisions regarding blood selection for transfusion 
and appropriate pregnancy management. Nevertheless, there 
are a significant number of rarer antibodies for which we have 
limited or no information available. Therefore, it is important 
to remember that our evidence base can only grow and 
strengthen by actively reporting clinical cases that describe 
these antibodies and the subsequent clinical outcomes, both 
good and bad.
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